Analysis of Lung Cancer Incidence, Mortality Trends, and Smoking Rates in Japan:1975-2022 with Insights on the Impact of COVID-19

Overview

Journal Int J Clin Oncol

Date 2025 Jan 17

PMID 39821472

Authors

Hiroki Yamamoto

Masayuki Shirasawa

Katsuhiko Naoki

Affiliations

Soon will be listed here.

Abstract

In Japan, high-quality cancer statistics are collected through cancer registries. However, these data are rarely summarized or reported in research articles. We compiled statistical data on lung cancer in Japan including the COVID-19 pandemic. In 2019, the number of cases of lung cancer in Japan was 126,548. The age-adjusted incidence rate of lung cancer increased from 23.2/100,000 to 42.4/100,000 in males and from 7.2/100,000 to 18.3/100,000 in females between 1975 and 2019. The age-adjusted mortality rate of lung cancer in Japan increased since 2000, after which it decreased. This trend was similar in both males and females. We also investigated statistics on lung cancer worldwide (Australia, Sweden, England, and the United States [USA]). The age-adjusted incidence rate of lung cancer in the data standardized to the world population for males has increased only in Japan; for females, it has decreased only in the USA. Global age-adjusted lung cancer mortality rates have been declining in all countries. In addition, the COVID-19 pandemic has not affected the age-adjusted mortality rate of lung cancer. On the other hand, the number of individuals undergoing lung cancer screening in Japan decreased from 7.92 million in 2019 to 6.59 million in 2020. The COVID-19 pandemic may have affected individuals undergoing lung cancer screening, and its impact on lung cancer needs to be continuously monitored in the future.

References

Sung H, Ferlay J, Siegel R, Laversanne M, Soerjomataram I, Jemal A . Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021; 71(3):209-249. DOI: 10.3322/caac.21660. View

Horinouchi H, Kusumoto M, Yatabe Y, Aokage K, Watanabe S, Ishikura S . Lung Cancer in Japan. J Thorac Oncol. 2022; 17(3):353-361. DOI: 10.1016/j.jtho.2021.11.020. View

Sobue T . A case-control study for evaluating lung cancer screening in Japan. Cancer. 2001; 89(11 Suppl):2392-6. DOI: 10.1002/1097-0142(20001201)89:11+<2392::aid-cncr13>3.3.co;2-a. View

Punekar S, Shum E, Grello C, Lau S, Velcheti V . Immunotherapy in non-small cell lung cancer: Past, present, and future directions. Front Oncol. 2022; 12:877594. PMC: 9382405. DOI: 10.3389/fonc.2022.877594. View

Chirieac L, Dacic S . Targeted Therapies in Lung Cancer. Surg Pathol Clin. 2010; 3(1):71-82. PMC: 2912609. DOI: 10.1016/j.path.2010.04.001. View

Nakatani H . Population aging in Japan: policy transformation, sustainable development goals, universal health coverage, and social determinates of health. Glob Health Med. 2020; 1(1):3-10. PMC: 7731274. DOI: 10.35772/ghm.2019.01011. View

Spiro S, Silvestri G . One hundred years of lung cancer. Am J Respir Crit Care Med. 2005; 172(5):523-9. DOI: 10.1164/rccm.200504-531OE. View

Redpath T . MRI developments in perspective. Br J Radiol. 1998; 70 Spec No:S70-80. DOI: 10.1259/bjr.1997.0010. View

Townsend D . Combined positron emission tomography-computed tomography: the historical perspective. Semin Ultrasound CT MR. 2008; 29(4):232-5. PMC: 2777694. DOI: 10.1053/j.sult.2008.05.006. View

10.

Urikura A, Yoshida T, Matsubara K, Nomura K, Hoshino T, Takagi T . Number of computed tomography scanners and regional disparities based on population and medical resources in Japan. Radiol Phys Technol. 2023; 16(3):355-365. DOI: 10.1007/s12194-023-00725-2. View

11.

Huang F, Pan B, Wu J, Chen E, Chen L . Relationship between exposure to PM2.5 and lung cancer incidence and mortality: A meta-analysis. Oncotarget. 2017; 8(26):43322-43331. PMC: 5522148. DOI: 10.18632/oncotarget.17313. View

12.

Thandra K, Barsouk A, Saginala K, Aluru J, Barsouk A . Epidemiology of lung cancer. Contemp Oncol (Pozn). 2021; 25(1):45-52. PMC: 8063897. DOI: 10.5114/wo.2021.103829. View

13.

Nagasawa T, Saito J, Odawara M, Imamura H, Kaji Y, Yuwaki K . Smoking cessation interventions and implementations in Japan: a study protocol for a scoping review and supplemental survey. BMJ Open. 2023; 12(12):e063912. DOI: 10.1136/bmjopen-2022-063912. View

14.

Tabuchi T, Nakamura M, Nakayama T, Miyashiro I, Mori J, Tsukuma H . Tobacco Price Increase and Smoking Cessation in Japan, a Developed Country With Affordable Tobacco: A National Population-Based Observational Study. J Epidemiol. 2015; 26(1):14-21. PMC: 4690736. DOI: 10.2188/jea.JE20140183. View

15.

Nguyen P, Katanoda K, Saito E, Hori M, Nakayama T, Matsuda T . Trends in lung cancer incidence by gender, histological type and stage at diagnosis in Japan, 1993 to 2015: A multiple imputation approach. Int J Cancer. 2022; 151(1):20-32. PMC: 9303961. DOI: 10.1002/ijc.33962. View

16.

Ohe Y, Ohashi Y, Kubota K, Tamura T, Nakagawa K, Negoro S . Randomized phase III study of cisplatin plus irinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcitabine, and cisplatin plus vinorelbine for advanced non-small-cell lung cancer: Four-Arm Cooperative Study in Japan. Ann Oncol. 2006; 18(2):317-23. DOI: 10.1093/annonc/mdl377. View

17.

Schiller J, Harrington D, Belani C, Langer C, Sandler A, Krook J . Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med. 2002; 346(2):92-8. DOI: 10.1056/NEJMoa011954. View

18.

Kubota K, Watanabe K, Kunitoh H, Noda K, Ichinose Y, Katakami N . Phase III randomized trial of docetaxel plus cisplatin versus vindesine plus cisplatin in patients with stage IV non-small-cell lung cancer: the Japanese Taxotere Lung Cancer Study Group. J Clin Oncol. 2004; 22(2):254-61. DOI: 10.1200/JCO.2004.06.114. View

19.

Fukuoka M, Wu Y, Thongprasert S, Sunpaweravong P, Leong S, Sriuranpong V . Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS). J Clin Oncol. 2011; 29(21):2866-74. DOI: 10.1200/JCO.2010.33.4235. View

20.

Hata M, Koike I, Wada H, Miyagi E, Kasuya T, Kaizu H . Radiation therapy for extramammary Paget's disease: treatment outcomes and prognostic factors. Ann Oncol. 2013; 25(1):291-7. DOI: 10.1093/annonc/mdt478. View